News & Updates

Show Multimedia Only

Casirivimab-imdevimab combo prevents progression from asymptomatic to symptomatic COVID-19

10 Feb 2022 by

Treatment with the combination therapy of casirivimab and imdevimab prevents the risk of developing symptomatic COVID-19 among asymptomatic individuals with SARS-CoV-2 infection in a household close-contact setting, according to a recent study.

Casirivimab-imdevimab combo prevents progression from asymptomatic to symptomatic COVID-19

10 Feb 2022

Could chewing xylitol gum daily prevent preterm birth?

09 Feb 2022 by

Chewing xylitol gum daily was associated with a reduced risk of preterm birth, according to a trial conducted in Malawi and presented at SMFM 2022.

Could chewing xylitol gum daily prevent preterm birth?

09 Feb 2022

Dose-escalated oral antidiabetic drug therapy may be less potent than reported

09 Feb 2022 by

In the real-world treatment of Asian patients with type 2 diabetes mellitus (T2DM), the blood glucose-lowering benefit following oral antidiabetic drug (OAD) dose escalation is lesser than what has been reported in clinical trials, according to a study from Singapore.

Dose-escalated oral antidiabetic drug therapy may be less potent than reported

09 Feb 2022

Aspirin boosts survival in multiple myeloma

09 Feb 2022

Multiple myeloma patients who use aspirin regularly show a survival advantage over their counterparts who do not use said agent, a study has found.

Aspirin boosts survival in multiple myeloma

09 Feb 2022

SSRIs may protect against noncardioembolic ischaemic stroke

09 Feb 2022

Use of selective serotonin reuptake inhibitors (SSRIs) poses no risk of noncardioembolic ischaemic stroke and is even protective when compared with other antidepressants, according to a recent study.

SSRIs may protect against noncardioembolic ischaemic stroke

09 Feb 2022

Appendicolith ups appendectomy risk after antibiotic treatment for acute appendicitis

08 Feb 2022 by

The presence of appendicolith is tied to an almost twofold risk of requiring an appendectomy within 30 days in patients who initially received antibiotic therapy for acute uncomplicated appendicitis, according to an analysis of the CODA* study from the US.

Appendicolith ups appendectomy risk after antibiotic treatment for acute appendicitis

08 Feb 2022

Probiotic use in IBD: Yay or nay?

08 Feb 2022 by

Using the probiotic Escherichia coli Nissle 1917 (EcN) as add-on therapy for patients with mild-to-moderate ulcerative colitis (UC) helps induce disease remission and preserve quality of life (QoL) in these patients, according to studies presented at CCC 2022.

Probiotic use in IBD: Yay or nay?

08 Feb 2022

Esmethadone clears phase II trial as adjunctive treatment for major depressive disorder

08 Feb 2022

REL-1017 (esmethadone), a novel N-methyl-D-aspartate receptor channel blocker, demonstrates favourable safety, tolerability, and pharmacokinetic profiles and appears to have rapid and sustained antidepressant effects relative to placebo in major depressive disorder patients with inadequate responses to antidepressant treatments, according to a recent study.

Esmethadone clears phase II trial as adjunctive treatment for major depressive disorder

08 Feb 2022

Apatinib a new treatment alternative for thyroid cancer?

08 Feb 2022 by

In individuals with progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC), the VEGFR-2* inhibitor apatinib demonstrated significant clinical benefits in terms of progression-free survival (PFS) and overall survival (OS), with a manageable safety profile, findings from the phase III REALITY trial suggest.

Apatinib a new treatment alternative for thyroid cancer?

08 Feb 2022

Novel XPO1 inhibitor shows antitumour activity in recurrent glioblastoma

08 Feb 2022

The oral selective inhibitor of exportin-1 (XPO1) selinexor has therapeutic potential in recurrent glioblastoma, yielding favourable responses and clinically relevant 6-month progression-free survival (PFS) rate with manageable side effects requiring dose reductions, according to the results of a phase II trial.

Novel XPO1 inhibitor shows antitumour activity in recurrent glioblastoma

08 Feb 2022

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Casirivimab-imdevimab combo prevents progression from asymptomatic to symptomatic COVID-19

Casirivimab-imdevimab combo prevents progression from asymptomatic to symptomatic COVID-19

Could chewing xylitol gum daily prevent preterm birth?

Could chewing xylitol gum daily prevent preterm birth?

Dose-escalated oral antidiabetic drug therapy may be less potent than reported

Dose-escalated oral antidiabetic drug therapy may be less potent than reported

Aspirin boosts survival in multiple myeloma

Aspirin boosts survival in multiple myeloma

SSRIs may protect against noncardioembolic ischaemic stroke

SSRIs may protect against noncardioembolic ischaemic stroke

Appendicolith ups appendectomy risk after antibiotic treatment for acute appendicitis

Appendicolith ups appendectomy risk after antibiotic treatment for acute appendicitis

Probiotic use in IBD: Yay or nay?

Probiotic use in IBD: Yay or nay?

Esmethadone clears phase II trial as adjunctive treatment for major depressive disorder

Esmethadone clears phase II trial as adjunctive treatment for major depressive disorder

Apatinib a new treatment alternative for thyroid cancer?

Apatinib a new treatment alternative for thyroid cancer?

Novel XPO1 inhibitor shows antitumour activity in recurrent glioblastoma

Novel XPO1 inhibitor shows antitumour activity in recurrent glioblastoma